Research Catalog

  • Burger's medicinal chemistry and drug discovery.

    • Text
    • Hoboken, N.J. : Wiley, c2003.
    • 2003
    • 12 Items

    Available Online

    http://www.loc.gov/catdir/toc/wiley031/2002044608.html
    FormatCall NumberItem Location
    Text JSM 03-48 Library has: Vol. 1-6.Schwarzman Building - Main Reading Room 315
    Not available - Please for assistance.
    FormatCall NumberItem Location
    Text JSM 03-48 v. 6Offsite
    FormatCall NumberItem Location
    Text JSM 03-48 Library has: Vol. 1-6.Schwarzman Building - Main Reading Room 315
    Not available - Please for assistance.
  • Innovation in the pharmaceutical industry : the process of drug discovery and development / Takuji Hara.

    • Text
    • Cheltenham, UK ; Northampton, MA : Edward Elgar, c2003.
    • 2003
    • 1 Item
    FormatCall NumberItem Location
    Text JBE 03-1389Offsite
  • Development and evaluation of drugs : from laboratory through licensure to market / Chi-Jen Lee, Lucia H. Lee, Cheng-Hsiung Lu.

    • Text
    • Boca Raton : CRC Press, c2003.
    • 2003
    • 1 Item
    FormatCall NumberItem Location
    Text JBE 04-1805Offsite
  • Drug discovery and development / edited by Mukund S. Chorghade.

    • Text
    • Hoboken, N.J. : Wiley-Interscience, c2006-
    • 2006-2007
    • 2 Items

    Available Online

    http://www.loc.gov/catdir/toc/ecip0516/2005021297.html
    FormatCall NumberItem Location
    Text JBF 18-498 v. 1Schwarzman Building - General Research Room 315

    Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.

    FormatCall NumberItem Location
    Text JBF 18-498 v. 2Schwarzman Building - General Research Room 315

    Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.

  • Drug discovery : from bedside to Wall Street / by Tamas Bartfai, Graham V. Lees.

    • Text
    • Amsterdam ; Boston : Elsevier Academic, c2006.
    • 2006
    • 1 Item
    FormatCall NumberItem Location
    Text JBE 06-602Offsite
  • Dose finding in drug development / Naitee Ting, editor.

    • Text
    • New York, NY : Springer, c2006.
    • 2006
    • 1 Item

    Available Online

    http://www.loc.gov/catdir/toc/fy0606/2005935288.html
    FormatCall NumberItem Location
    Text JBE 06-1065Offsite
  • American drug discovery.

    • Text
    • Indianapolis, Ind. : Russell Pub., 2006-
    • 2006-present
    • 1 Item
    FormatCall NumberItem Location
    Text JBM 08-181 v. 3, no. 1, 3-6 (Dec-Nov 2007-2008)Offsite
  • Biochips as pathways to drug discovery / edited by Andrew Carmen, Gary Hardiman.

    • Text
    • Boca Raton, FL : CRC Press/Taylor & Francis, c2007.
    • 2007
    • 1 Item
    FormatCall NumberItem Location
    Text JSE 07-608Offsite
  • In silico technologies in drug target identification and validation / edited by Darryl León, Scott Markel.

    • Text
    • Boca Raton : CRC/Taylor & Francis, c2006.
    • 2006
    • 1 Item

    Available Online

    http://www.loc.gov/catdir/toc/ecip068/2006005722.html
    FormatCall NumberItem Location
    Text JSE 07-1131Offsite
  • Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Tenth Congress, first session, special hearing, June 1, 2007, Salt Lake City, Utah.

    • Text
    • Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008.
    • 2008
    • 2 Resources

    Available Online

    See All Available Online Resources

  • Innovation in the biopharmaceutical industry / editors, Rifat A. Atun, Desmond Sheridan.

    • Text
    • Hackensack, N.J. : World Scientific Pub., c2007.
    • 2007
    • 1 Item

    Available Online

    http://www.loc.gov/catdir/toc/ecip0710/2007004943.html
    FormatCall NumberItem Location
    Text JSF 08-332Offsite
  • Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.

    • Text
    • Washington : U.S. G.P.O., 2008.
    • 2008
    • 2 Resources

    Available Online

    See All Available Online Resources

  • Outsourcing clinical development : strategies for working with CROs and other partners / edited by Jane E. Winter and Jane Baguley.

    • Text
    • Aldershot, England ; Burlington, VT : Gower Pub., c2006.
    • 2006
    • 1 Item
    FormatCall NumberItem Location
    Text JBG 09-171Offsite
  • E2f development safety update report.

    • Text
    • [Silver Spring, MD] : [Center for Drug Evaluation and Research] ; [Rockville, MD] : [U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research], [2008]
    • 2008
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS111600
  • Information sheet guidance for sponsors, clinical investigators, and IRBs : frequently asked questions, statement of investigator (form FDA 1572).

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, [2008]
    • 2008
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS111644
  • Guidance for industry : community-acquired bacterial pneumonia : developing drugs for treatment.

    • Text
    • Silver Spring, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, [2009]
    • 2009
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS112221
  • Guidance for industry : influenza, developing drugs for treatment and/or prophylaxis.

    • Text
    • Silver Spring, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, [2009]
    • 2009
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS112225
  • Guidance for industry and FDA : current good manufacturing practice for combination products.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Combination Products, [2004]
    • 2004
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS112968
  • Guidance for industry and FDA staff [electronic resource] : early development considerations for innovative combination products.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Combination Products, [2006]
    • 2006
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113681
  • Guidance for industry [electronic resource] : Q3A impurities in new drug substances.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [2008]
    • 2008
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113736
  • Guidance for industry [electronic resource] : fast track drug development programs, designation, development and application review.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [2006]
    • 2006
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113471
  • Guidance for industry [electronic resource] : Q3B(R2) impurities in new drug products.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, [2006]
    • 2006
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113762
  • Guidance for industry [electronic resource] : E2E pharmacovigilance planning.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [2005]
    • 2005
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113917
  • Q8(R1) pharmaceutical development revision 1 [electronic resource].

    • Text
    • [Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, 2008?]
    • 2008
    • 1 Resource

    Available Online

    http://purl.access.gpo.gov/GPO/LPS113761
  • 1570 : innovation for new medicines for infectious diseases.

    • Text
    • Paris : OECD, c2009.
    • 2009
    • 1 Item

    Available Online

    http://www.sourceoecd.org/9789264060142
    FormatCall NumberItem Location
    Text JBE 09-1570Schwarzman Building - General Research Room 315

    Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.

  • Guidance : PET drug products, current good manufacturing practice (CGMP).

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, [2005]
    • 2005
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS116533
  • Guidance for industry : Q8(R2) pharmaceutical development.

    • Text
    • Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [2009]
    • 2009
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS117887
  • Follow-on biologics [microform] : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.

    • Text
    • Washington : U.S. G.P.O., 2008.
    • 2008
  • Biologics and biosimilars [microform] : balancing incentives for innovation : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, July 14, 2009.

    • Text
    • Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2010.
    • 2010
  • Food and Drug Administration's review process for products to treat rare diseases and neglected tropical diseases [microform] : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eleventh Congress, second session, special hearing, June 23, 2010, Washington, D.C.

    • Text
    • Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2011.
    • 2011
  • PDUFA V : medical innovation, jobs, and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, July 7, 2011.

    • Text
    • Washington : U.S. G.P.O., 2012.
    • 2012
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo26461
  • Q8(R1) pharmaceutical development revision 1 [electronic resource].

    • Text
    • [Rockville, MD] : [U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research] : [Center for Biologics Evaluation and Research], [2008?]
    • 2008
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/LPS113761
  • The high cost of high prices for HIV/AIDS drugs and the prize fund alternative : hearing before the Subcommittee on Primary Health and Aging of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, second session ... May 15, 2012.

    • Text
    • Washington : U.S. G.P.O., 2012.
    • 2012
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo30915
  • Curtis Powell papers, 1935-2002 (bulk 1968-2002).

    • Mixed material
    • 1935-2002
    • 2 Items

    Available Online

    http://archives.nypl.org/scm/22377
    FormatCall NumberItem Location
    Mixed material Sc MG 877 box 2Schomburg Center - Manuscripts & Archives

    Available - Can be used on site. Please visit New York Public Library - Schomburg Center to submit a request in person.

    FormatCall NumberItem Location
    Mixed material Sc MG 877 box 1Schomburg Center - Manuscripts & Archives

    Available - Can be used on site. Please visit New York Public Library - Schomburg Center to submit a request in person.

  • Les hommes et les plantes : valorisation des ressources de la médecine traditionnelle à Kadiolo (Mali) / Sergio Giani.

    • Text
    • Bamako : EDIMCO MALI, 2010.
    • 2010
    • 1 Item
    FormatCall NumberItem Location
    Text Sc E 13-622Offsite
  • The pharmaceutical industry [electronic resource] / Jamuna Carroll, book editor.

    • Text
    • Detroit : Greenhaven Press, c2009.
    • 2009
    • 2 Resources

    Available Online

    See All Available Online Resources

  • FDA checkup : drug development and manufacturing challenges : hearing before the Subcommittee on Energy Policy, Health Care and Entitlements of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Thirteenth Congress, first session, December 12, 2013.

    • Text
    • Washington : U.S. Government Printing Office, 2014.
    • 2014
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo49004
  • Conservatism, consumer choice, and the Food and Drug Administration during the Reagan era : a prescription for scandal / Lucas Richert.

    • Text
    • Lanham, Maryland ; Plymouth, United Kingdom : Lexington Books, [2014]
    • 2014
    • 1 Item
    FormatCall NumberItem Location
    Text JFE 14-5708Schwarzman Building - Main Reading Room 315

    Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.

  • FDA checkup : drug development and manufacturing challenges : hearing before the Subcommittee on Energy Policy, Health Care and Entitlements of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Thirteenth Congress, first session, December 12, 2013.

    • Text
    • [Washington, District of Columbia] : U.S. Government Printing Office, [2014]
    • 2014
  • Medical monopoly : intellectual property rights and the origins of the modern pharmaceutical industry / Joseph M. Gabriel.

    • Text
    • Chicago : The University of Chicago Press, [2014]
    • 2014-2014
    • 1 Item
    FormatCall NumberItem Location
    Text JFE 14-8232Schwarzman Building - Main Reading Room 315

    Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.

  • PDUFA V : medical innovation, jobs, and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, July 7, 2011.

    • Text
    • [Washington, District of Columbia] : U.S. Government Printing Office, [2012]
    • 2012
  • Twenty-first century cures : examining the roles of incentives in advancing treatments and cures for patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, June 11, 2014.

    • Text
    • Washington : U.S. Government Printing Office, 2014.
    • 2014
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo54770
  • The high cost of high prices for HIV/AIDS drugs and the prize fund alternative : hearing before the Subcommittee on Primary Health and Aging of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, second session on ... S. 1137 ... and S. 1138 ... May 15, 2012.

    • Text
    • Washington : U.S. Government Printing Office, 2012.
    • 2012
  • 21st century cures : the President's Council of Advisors on Science and Technology (PCAST) report on drug innovation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, May 20, 2014.

    • Text
    • Washington : U.S. Government Publishing Office, 2015.
    • 2015
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo55610
  • 21st century cures : incorporating the patient perspective : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, July 11, 2014.

    • Text
    • Washington : U.S. Government Publishing Office, 2015.
    • 2015
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo56008
  • Twenty-first century cures : examining the roles of incentives in advancing treatments and cures for patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, June 11, 2014.

    • Text
    • Washington : U.S. Government Printing Office, 2014.
    • 2014
  • 21st century cures : the President's Council of Advisors on Science and Technology (PCAST) report on drug innovation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, May 20, 2014.

    • Text
    • Washington : U.S. Government Publishing Office, 2015.
    • 2015
  • 21st century cures : incorporating the patient perspective : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, July 11, 2014.

    • Text
    • Washington : U.S. Government Publishing Office, 2015.
    • 2015
  • 21st Century Cures Act : report of the Committee on Energy and Commerce, House of Representatives (to accompany H.R. 6).

    • Text
    • [Washington, D.C.] : [U.S. Government Publishing Office], [2015]-
    • 2015-present
    • 1 Resource

    Available Online

    https://purl.fdlp.gov/GPO/gpo58917
  • 21st Century Cures Act : report of the Committee on Energy and Commerce, House of Representatives (to accompany H.R. 6).

    • Text
    • [Washington, D.C.] : [U.S. Government Publishing Office], [2015]-
    • 2015-present

No results found from Digital Research Books Beta

Digital books for research from multiple sources world wide- all free to read, download, and keep. No Library Card is Required. Read more about the project.

digital-research-book
Explore Digital Research Books Beta